Internal Medicine, Medical Oncology · Cincinnati, OH
NPI
1699768499
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
601 Ivy Gtwy Ste 1100
Cincinnati, OH, 45245
Phone (513) 751-2273
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
120,631 services
Medicare patients, 2024
725
Average age 73
Drug cost, 2024
$6.0M
3,509 prescriptions
Company payments, 2025
$2,074
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Drosick was code J9299 (injection, nivolumab, 1 mg), 16,160 times for 11 patients. In total David R Drosick billed 120,631 services in 141 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 16,160 | 11 | $24.18 | $391K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,216 | 17 | $44.79 | $637K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,820 | 13 | $0.08 | $621 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,000 | 19 | $0.11 | $663 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,800 | 23 | $15.72 | $44K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,732 | 59 | $0.09 | $150 |
| J0897 Injection, denosumab, 1 mg | Office | 1,440 | 15 | $20.25 | $29K |
| 85025 Blood Count | Office | 1,091 | 443 | $7.59 | $8,283 |
| 80053 Clinical Chemistry | Office | 956 | 429 | $10.33 | $9,876 |
| 99213 Office E&M - Established | Office | 920 | 489 | $59.25 | $55K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 880 | 32 | $0.66 | $577 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 860 | 24 | $0.24 | $210 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 587 | 355 | $10.80 | $6,340 |
| 96413 Chemotherapy Administration | Office | 374 | 92 | $90.60 | $34K |
| J9045 Injection, carboplatin, 50 mg | Office | 257 | 13 | $2.77 | $711 |
By year: 2022 $2.1M for 148,280 services; 2023 $2.3M for 116,339 services; 2024 $2.2M for 120,631 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,091 | 443 | $7.59 | $8,283 |
| 80053 Clinical Chemistry | 956 | 429 | $10.33 | $9,876 |
| 82728 Clinical Chemistry | 158 | 107 | $13.36 | $2,111 |
| 83540 Clinical Chemistry | 144 | 98 | $6.34 | $913 |
| 83550 Clinical Chemistry | 143 | 97 | $8.57 | $1,226 |
| 82784 Immunoassay | 116 | 22 | $9.11 | $1,057 |
| 84443 Clinical Chemistry | 69 | 39 | $16.46 | $1,136 |
| 82607 Clinical Chemistry | 41 | 37 | $14.61 | $599 |
| 82378 Clinical Chemistry | 39 | 29 | $18.58 | $725 |
| 82746 Clinical Chemistry | 35 | 31 | $14.41 | $504 |
Medicare prescription drug claims, 2024
In 2024, the drug David R Drosick prescribed most often to Medicare patients was Anastrozole, with 511 prescriptions and refills. In total David R Drosick wrote 3,509 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 511 | 995 | 114 | $6,846 |
| Oxycodone Hcl Generic | 239 | 239 | 62 | $6,191 |
| Eliquis Apixaban | 175 | 211 | 32 | $122K |
| Ibrance Palbociclib | 124 | 124 | 14 | $1.9M |
| Morphine Sulfate Er Morphine Sulfate | 101 | 101 | 26 | $3,209 |
| Levothyroxine Sodium Generic | 95 | 157 | 20 | $514 |
| Ondansetron Hcl Generic | 90 | 96 | 37 | $15K |
| Duloxetine Hcl Generic | 83 | 109 | 17 | $1,204 |
| Letrozole Generic | 80 | 165 | 21 | $1,682 |
| Prednisone Generic | 79 | 97 | 23 | $412 |
| Hydroxyurea Generic | 65 | 125 | 20 | $899 |
| Potassium Chloride Generic | 64 | 105 | 17 | $626 |
| Gabapentin Generic | 63 | 65 | 14 | $461 |
| Promethazine Hcl Generic | 63 | 63 | Under 11 | $195 |
| Olanzapine Generic | 53 | 55 | 23 | $318 |
Brand drugs: 723 claims; generic drugs: 2,786 claims; opioid claims: 502.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David R Drosick $2,074 ($2,074 in general payments such as food, travel and fees) from 31 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,235.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 22 | $1,235 |
| Abbvie Inc. ABBV | 2 | $60.38 |
| Gilead Sciences, Inc. GILD | 2 | $50.89 |
| Pfizer Inc. PFE | 3 | $49.09 |
| PharmaEssentia USA Corporation 6446.TW | 2 | $44.35 |
| Merck Sharp & Dohme LLC MRK | 2 | $43.01 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $41.71 |
| Aveo Pharmaceuticals, Inc. | 2 | $39.6 |
| Eisai Inc. 4523.T | 2 | $38.33 |
| Sobi, Inc SOBI.ST | 1 | $36.06 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.